Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIOngoingJul 3, 2024Buprenorphine Hydrochloride InjectionLack of Assurance of Sterility-The potential for incomplete crimp seals.Pfizer Inc. · D-0564-2024Class IICompletedJul 3, 2024Progesterone 200 mgPresence of Foreign Substance; Broken metal piece found embedded in tablet.Coast Quality Pharmacy, LLC dba Anazao Health · D-0563-2024Class IITerminatedJun 26, 2024Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limitBreckenridge Pharmaceutical, Inc · D-0562-2024Class IIOngoingJun 26, 2024Amoxicillin and Clavulanate Potassium Tablets USPSubpotent DrugTeva Pharmaceuticals USA, Inc · D-0561-2024Class IITerminatedJun 26, 2024Petroleum JellyLabeling: Label Mix up; product labeled as pure white petroleum jelly actually contains petroleum jelly with Lavendar and ChamomileConsumer Product Partners, LLC · D-0560-2024Class IITerminatedJun 26, 2024Cefixime for Oral Suspension USP 200 mg/5 mLFailed Content Uniformity SpecificationsLupin Pharmaceuticals Inc. · D-0559-2024Class IIOngoingJun 26, 2024OSSOS-SANS Reforzado con: Glucosamina Curcuma Ortiga tabletsMarketed Without An Approved NDA/ANDA: FDA laboratory analysis found the product to contain undeclared diclofenac and methocarbamol,MexHealth LLC · D-0558-2024Class IITerminatedJun 26, 2024Little Remedies Gas Relief DropscGMP deviations: Test results confirmed aypical Burkholderia Cepacia were a result of personnel error.Denison Pharmaceuticals, LLC · D-0557-2024Class IIIOngoingJun 26, 2024Eptifibatide injection 20mg/10mLFailed Impurities/Degradation Specifications: failed related substance identified as Eptifibatide dimer.Eugia US LLC · D-0556-2024Class IIOngoingJun 26, 2024Dexamethasone Sodium Phosphate injection USPFailed Impurities/Degradation Specifications: impurity sulfonic acid adduct of dexamethasone phosphate results were above spec.Eugia US LLC · D-0555-2024Class IOngoingJun 19, 2024Docetaxel InjectionPresence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.Sagent Pharmaceuticals · D-0554-2024Class IOngoingJun 19, 2024Docetaxel InjectionPresence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.Sagent Pharmaceuticals · D-0553-2024Class IIIOngoingJun 19, 2024Asmanex TwisthalerDefective ContainerOrganon Llc · D-0552-2024Class IIIOngoingJun 19, 2024Asmanex TwisthalerDefective ContainerOrganon Llc · D-0551-2024Class IIIOngoingJun 19, 2024Asmanex TwisthalerDefective ContainerOrganon Llc · D-0550-2024Class IITerminatedJun 19, 2024Phenazopyridine HClProduct Mix Up. A bottle labeled as Phenazopyridine HCl tablets USP 100 mg contained Phenobarbital tablets 16.2 mg.RemedyRepack Inc. · D-0549-2024Class IIOngoingJun 19, 2024Prednisolone-Moxifloxacin-Bromfenac Sterile Ophthalmic SuspensionLack of Assurance of SterilityImprimis NJOF, LLC · D-0548-2024Class IIOngoingJun 19, 2024Klarity-CLack of Assurance of SterilityImprimis NJOF, LLC · D-0547-2024Class IIOngoingJun 19, 2024Drug Vial Label: Zilretta¿Failed Stability Specifications - at 12 months 2-8 degrees C followed by 6 weeks at 25 degrees C.Pacira Pharmaceuticals Inc · D-0546-2024Class IICompletedJun 19, 2024Phenazopyridine HCl Tablets USPProduct Mix Up. A bottle of Phenazopyridine HCl tablets USP 100 mg contained Phenobarbital tablets 16.2 mg.Winder Laboratories, LLC · D-0545-2024Class IIITerminatedJun 12, 2024Tivicay PDLabeling: Incorrect Lot and/or Expiration Date: The carton has incorrect expiration of 2026-MAY*, whereas the correct expiration date, which is on the tablet bottle...GlaxoSmithKline LLC · D-0544-2024Class IIIOngoingJun 12, 2024Estradiol Transdermal SystemFailed Impurities/Degradation Specifications.Zydus Pharmaceuticals (USA) Inc · D-0543-2024Class IIIOngoingJun 12, 2024Estradiol Transdermal SystemFailed Impurities/Degradation Specifications.Zydus Pharmaceuticals (USA) Inc · D-0542-2024Class IIIOngoingJun 12, 2024Pregabalin Capsules 50mgPresence of Foreign Tablets/Capsules: Complaint received from a re-packager, American Health Packaging (AHP), where a foreign tablet was discovered in one of the bottles...Rising Pharma Holding, Inc. · D-0541-2024Class IIIOngoingJun 12, 2024Cephalexin for Oral SuspensionLabeling: Not Elsewhere Classified: Back Label states 'Each contains: cephalexin monohydrate, USP equivalent to 5g' instead of Each Bottle contains: cephalexin...Bryant Ranch Prepack, Inc. · D-0540-2024Class IIIOngoingJun 12, 2024Cephalexin for Oral SuspensionLabeling: Not Elsewhere Classified: Back Label states Each contains: cephalexin monohydrate, USP equivalent to 5g' on the back label instead of Each Bottle contains...Bryant Ranch Prepack, Inc. · D-0539-2024Class IIIOngoingJun 12, 2024Cephalexin for Oral SuspensionLabeling: Not Elsewhere Classified: Back Label states 'Each contains: cephalexin monohydrate, USP equivalent to 5g' instead of Each Bottle contains: cephalexin...Bryant Ranch Prepack, Inc. · D-0538-2024Class IIIOngoingJun 12, 2024Cephalexin for Oral SuspensionLabeling: Not Elsewhere Classified: Back label states Each contains: cephalexin monohydrate, USP equivalent to 2.5g' instead of Each Bottle contains: cephalexin...Bryant Ranch Prepack, Inc. · D-0537-2024Class IIIOngoingJun 12, 2024Cephalexin for Oral SuspensionLabeling: Not Elsewhere Classified: Front label states 100 Tablets instead of 100 ml and on the back label 'Each Tablet contains' instead of 'Each Bottle contains' No...Bryant Ranch Prepack, Inc. · D-0536-2024Class IIOngoingJun 12, 2024Rizatriptan Benzoate Orally Disintegrating TabletsCGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.Glenmark Pharmaceuticals Inc., USA · D-0535-2024Class IIOngoingJun 12, 2024Rizatriptan Benzoate Orally Disintegrating TabletsCGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.Glenmark Pharmaceuticals Inc., USA · D-0534-2024Class IIOngoingJun 12, 2024Rizatriptan Benzoate Tablets USPCGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.Glenmark Pharmaceuticals Inc., USA · D-0533-2024Class IIOngoingJun 12, 2024Rizatriptan Benzoate Tablets USPCGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.Glenmark Pharmaceuticals Inc., USA · D-0532-2024Class IITerminatedJun 5, 2024EYLEA, (aflibercept) InjectionLack of Assurance of Sterility: Complaints of syringe breakageRegeneron Pharmaceuticals Inc · D-0531-2024Class IIOngoingJun 5, 2024ALOE GATOROut of Specification for active ingredientARG Laboratories, Inc. · D-0530-2024Class IIOngoingJun 5, 2024NATURAL PAIN RELIEVING CREAMOut of Specification for active ingredient. Violative grade of propylene glycol used during the manufacturing process.ARG Laboratories, Inc. · D-0529-2024Class IIOngoingJun 5, 2024Pain WizardOut of Specification for active ingredient. Violative grade of propylene glycol used during the manufacturing process.ARG Laboratories, Inc. · D-0528-2024Class IIOngoingJun 5, 2024NATURAL PAIN RELIEVING CREAMOut of Specification for active ingredient. Violative grade of propylene glycol used during the manufacturing process.ARG Laboratories, Inc. · D-0527-2024Class IIOngoingJun 5, 2024NATURAL PAIN RELIEVING CREAMOut of Specification for active ingredient. Violative grade of propylene glycol used during the manufacturing process.ARG Laboratories, Inc. · D-0526-2024Class IIOngoingJun 5, 2024Pain WizardOut of Specification for active ingredient. Violative grade of propylene glycol used during the manufacturing process.ARG Laboratories, Inc. · D-0525-2024